Medical Oncology

and Tumor Pharmacotherapy

Volume 6, 1989

PERGAMON PRESS
Oxford • New York
Beijing • Frankfurt • São Paulo • Sydney • Tokyo • Toronto

Medical Oncology and Tumor Pharmacotherapy

SENIOR EDITORS

James F. Holland, MD, Department of Neoplastic Diseases, Mt Sinai School of Medicine, New York, NY 10029, U.S.A.

Georges Mathé, MD, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul Brousse, 94800 Villejuif, France

Peter Reizenstein, MD, Division of Hematology, Karolinska Institute and Hospital, 10401 Stockholm, Sweden

COORDINATING EDITOR

Peter Reizenstein, MD, Division of Hematology, Karolinska Institute and Hospital, 10401 Stockholm, Sweden

ASSOCIATE EDITORS

Paul Calabresi, MD, Department of Medicine, Roger Williams General Hospital, Brown University, Providence, RI 02912, U.S.A.

Kiyoji Kimura, MD, National Nagoya Hospital, 4-1-1, Sannomaru, Naka-ku, Nagoya 460, Japan

J. M. A. Whitehouse, MD, C.R.C. Medical Oncology Unit, Centre Block CP 99, Southampton SO9 4XY, United Kingdom

P. Wiernik, MD, Department of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, U.S.A.

EDITORIAL BOARD

L. Andersson, *Stockholm* (Urology)
G. Bonadonna, *Milan* (Chemotherapy)
M. Dicato, *Luxembourg* (Diagnostic Oncology)
S. Dray, *Chicago* (Immunology)
N. Einhorn, *Stockholm* (Gynecology)
H. Fudenberg, *Charleston* (Immunology)
H. Hansen, *Copenhagen* (Lung Cancer)
M. Hansson, *Stockholm* (Immunology)
K. Harrap, *London* (Pharmacology)
R. Hast, *Stockholm* (Hematology)
E. M. Hersh, *Houston* (Immunology)
L.-E. Holm, *Stockholm* (Cancer Prevention)
K. Karrer, *Vienna* (Lung Cancer)
B. Littbrand, *Umeå* (Oncology)
J. McLaren, *Atlanta* (Hyperthermia)
T. Miale, *Knoxville* (Pediatric Oncology)
F. Mitelman, *Lund* (Cytogenetics)
B. Modan, *Tel Aviv* (Epidemiology)
B. Nordenskjöld, *Linköping* (Endocrinology)
R. T. D. Oliver, *London* (Urology)
C. Peterson, *Stockholm* (Pharmacology)
H. M. Pinedo, *Amsterdam* (Pharmacotherapy)
J. Ponten, *Uppsala* (Pathology)
H. D. Preisler, *Cincinnati* (Leukemia)
L. Sachs, *Jerusalem* (Differentiation)
C. Schmidt, *Essen* (Oncology)
M. Toga, *Marseilles* (Neurology)

Annual institutional subscription rate (1990) DM 280.00 (including postage and insurance). Two-year rate (1990/91) DM 532.00. Personal subscription rate for those whose library subscribes at the regular rate (1990) DM 120.00. Prices are subject to change without notice.

Published Quarterly

Publishing and Advertising Offices

Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A.
Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, U.K.

Back Issues

Back issues of all previously published journals, in both hard copy and on microform, are available direct from Pergamon Press offices.

Copyright © 1989 Pergamon Press plc

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required for authors who work for organisations which do not permit such assignments. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. Copyright Law Applicable to Users in the U.S.A.

Photocopying information for users in the U.S.A.: The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying.

The Item-Fee Code for this publication is: 0736-0118/89 $3.00 + .00.

List of Contents
Number 1

Editorial

P. REIZENSTEIN — 1 Role of biological response modifiers in the treatment of tumors

Therapeutic Use of Thymus Hormone Preparations

N. M. KOUTTAB, M. PRADA and P. CAZZOLA — 5 Thymomodulin: biological properties and clinical applications

J. W. HADDEN and E. M. HADDEN — 11 Therapy of secondary T-cell immunodeficiencies with biological substances and drugs

J. DUCHATEAU and K. BOLLA — 19 Immunomodulation with thymopentin: *in vitro* studies

J.-F. BACH and M. DARDENNE — 25 Thymulin, a zinc-dependent hormone

A. B. SKOTNICKI — 31 Therapeutic application of calf thymus extract (TFX)

A. M. LIBERATI, S. CINIERI, M. FIZZOTTI, M. SCHIPPA, S. ASCANI, V. De ANGELIS, M. SENATORE and L. PALMISANO — 45 Modulation of NK activity by thymic hormones: *in vitro* effects of thymostimulin

Clinical Use of Immunomodulating Agents in Treatment of AIDS

P. HERMANS and N. CLUMECK — 55 Preliminary results on clinical and immunological effects of thymus hormone preparations in AIDS

J.-L. TOURAINE — 59 Effect of the immunomodulator LF 1695 on T-lymphocytes and macrophages. Activity in HIV infection

C. De SIMONE, F. ALBERTINI, M. ALMAVIVA, G. ANGARANO, F. CHIODO, P. COSTIGLIOLA, S. DELIA, A. FERLINI, F. GRITTI, G. MAZZARELLO, F. MILAZZO, M. MONTRONI, P. NARCISO, G. PASTORE, E. RAISE, G. SANTINI, F. SORICE, A. TERRAGNA, G. VISCO and V. VULLO — 63 Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study

Clinical Use of Immunomodulating Agents

A. BRAVO-CUELLAR, G. MATHÉ and S. ORBACH-ARBOUYS — 71 4′-*O*-Tetrahydropyranyl adriamycin (THP-ADM)-induced modifications of murine peritoneal macrophages

S. DRAY and M. B. MOKYR — 77 Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy

H. STRANDER — 87 Clinical evaluation of treatment with interferon

E. LOTZOVÁ — 93 Cytotoxicity and clinical application of activated NK cells

H. MELLSTEDT, J. E. FRÖDIN, P. RAGNHAMMAR, G. MASUCCI, J. SHETYE, B. CHRISTENSSON, P. BIBERFELD, J. MAKOWER, P. PIHLSTEDT, B. CEDERMARK, U. HARMENBERG, B. WAHREN, Å. RIEGER, I. MAGNUSSON, J. NATHANSSON and R. ERWALD — 99 The clinical use of monoclonal antibodies, MAb 17–1A, in the treatment of patients with metastatic colorectal carcinoma

Number 1 (cont'd)

***In Vitro* Effect of Immunomodulating Agents**

R. HAST, P. BERNELL and M. HANSSON — 111 Cimetidine as an immune response modifier

Announcement — 115

Information for Authors — I

Number 2

Review

A. VON ROSEN — 117 Aneuploidy as a prognostic factor in breast cancer

Original Articles

T. BAUKNECHT, I. JANZ, M. KOHLER and A. PFLEIDERER — 121 Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F)

V. ABBASCIANO, F. LEVATO and G. ZAVAGLI — 129 Specificity of tumor markers (CEA, GICA, TPA, α-FP, FpA, γ-GT) for the diagnosis of hepatic metastases from large bowel cancers

E. ÖSBY and P. REIZENSTEIN — 133 Quality of life and care in leukemia, myeloma and non-malignant disease. Opinions of patients and relatives, and effects of geography and time

K. KARRER, H. DENCK, H. KARNICKA-MLODKOWSKA, P. DRINGS, J. OREL, G. M. SALZER, M. THERMANN, A. LATTUNEDDU, Y. SUN, E. HATA, B. BERKARDA, M. L. LIAO, F. BRUNO, J. ROTHMUND and H. OSADA — 143 The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC)

H. EHRSSON, S. EKSBORG, A. ÖSTERBORG, H. MELLSTEDT and A. LINDFORS — 151 Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma

V. DIEHL, M. PFREUNDSCHUH, M. LÖFFLER, U. RÜHL, E. HILLER, H. GERHARTZ, W. WILMANNS, H. KIRCHNER, W. SCHOPPE, S. PETSCH, H. BARTELS, K. H. PFLÜGER, J. TEICHMANN, R. FUCHS, G. KÜHN, W. OERTEL, R. MERTELSMANN, T. HECHT, K. P. SCHALK, P. WORST, M. WILHELMY, W. GASSMANN, U. LOOS, R. HINTERBERGER, H. THEML, T. WAGNER, S. SAMANDARI, W. SCHÄFGEN, J. PREISS, G. SCHMITZ, W. MENDE, B. MÖDDER and H. D. SCHICK — 155 Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group

M. DE LENA, E. MAIELLO, V. LORUSSO, M. BRANDI, P. CALABRESE, S. ROMITO, A. MAZZEI and F. MARZULLO — 163 Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial

Number 2 (cont'd)

H. O. KLEIN, J. WILS, H. BLEIBERG, M. BUYSE and N. DUEZ — 171 An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer

R. HENRIKSSON and K. GRANKVIST — 175 Epirubicin cytotoxicity but not oxygen radical formation is enhanced by four different antiemetics

A. VERONESI, V. DAL BO, S. MORASSUT, A. MERLO, G. CARMIGNANI, G. LO RE, A. CARBONE, M. D. MAGRI, R. TALAMINI, M. FRANCINI and S. MONFARDINI — 179 Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: a feasible and possibly effective approach

Book Reviews — 183

Announcements — 187

Number 3

Original Articles

C. C. OKANY and O. O. AKINYANJU — 189 Chronic leukaemia: an African experience

S. EKSBORG, U. STENDAHL and K. ANTILA — 195 Pharmacokinetics of 4′ epi-adriamycin after morning and afternoon intravenous administration

A. WAHLIN — 199 Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia

Y. HUMBLET, P. WEYNANTS, A. BOSLY, F. MAJOIS, P. DUPREZ, C. FRANCIS, M. BEAUDUIN, J. MACHIELS, C. GAILLY, L. DELAUNOIS, D. RODENSTEIN, C. DOYEN, J. LONGUEVILLE, C. MICHEL, D. SCHALLIER, J. PRIGNOT and M. SYMANN — 207 Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin

H. T. HASSAN and J. K. H. REES — 213 Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells

P. HENRIKSSON, M. BLOMBÄCK, G. BRATT, O. EDHAG, A. ERIKSSON and O. VESTERQVIST — 219 Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer

P. D. J. HARDMAN, J. A. GREEN, R. D. ERRINGTON, S. MYINT and H. M. WARENIUS — 227 Treatment of small cell lung cancer with induction chemotherapy followed by late intensification

Case Reports

E. DONTI, G. V. DONTI, F. FALZETTI, A. ROSETTI, F. GRIGNANI and A. TABILIO — 233 Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome

Number 3 (cont'd)

A. BOTELHO DE SOUSA and J. GOUVEIA — 239 Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment

Book Review — 241

Announcement — 243

Information for authors — i

Number 4

Original Articles

C. P. BURNS, B. A. WAGNER and J. A. NORTH — 245 Effect of hyperthermia on selective expression of HL-60 heat shock proteins

A. VERONESI, G. LO RE, V. DAL BO, M. D. MAGRI, M. D. VALENTINA, R. TALAMINI, A. MERLO, M. FRANCINI and S. MONFARDINI — 255 Buserelin treatment of advanced prostatic cancer: a phase II study

P. LAFOLIE, O. BJÖRK, S. HAYDER, L. ÅHSTRÖM and C. PETERSON — 259 Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia

P. HERAIT, J. P. ARMAND, M. BENAHMED, C. DOMENGE, X. FONTANA, G. RECONDO, E. CVITKOVIC and F. M. DELGADO — 267 Phase II study of mitozolomide (M & B 39, 565) in head and neck cancer

G. CORRADI, A. CAPPELLARI, R. POMARI and F. CAPPELLO — 271 Morphometric analysis of peritumoral lymph nodes in patients operated on for uterine cancer, locally treated with a thymic extract

W. SIEGERT, W. HIDDEMANN, R. KOPPENSTEINER, T. BÜCHNER, M. ESSINK, D. HUHN, M. JUNG, L. MAROSI, T. MARTIN and E. MINAR — 275 Accidental overdose of mitoxantrone in three patients

S. M. CRAWFORD, D. PARKER, M. G. GLASER, B. M. SOUTHCOTT, R. H. J. BEGENT, G. J. S. RUSTIN, E. S. NEWLANDS, A. J. WARD and K. D. BAGSHAWE — 279 Treatment of small cell lung cancer by eight weeks chemotherapy

U. RINGBORG, C.-M.RUDENSTAM, J. HANSSON, L. HAFSTRÖM, B. STENSTAM and H. STRANDER — 285 Dacarbazine versus dacarbazine–vindesine in disseminated malignant melanoma: a randomized phase II study

K. SAMPI, M. SAKURAI, R. KUMAI, N. MASEKI, Y. KANEKO and M. HATTORI — 291 Combination of pipemidic acid, colistin sodium methanesulfonate and nystatin may be less effective than nystatin alone for prevention of infection during chemotherapy-induced granulocytopenia in acute leukemia

Case Report

J. CASSIDY and E. M. RANKIN — 297 Hypersensitivity reaction to epirubicin

Volume Contents and Author Index for Volume 6, 1989 — i

Information for authors — ix